The report forecasts the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend resulting in the strong growth of this market is the advent of biologics with novel MOA and cell-based strategies. This market is expected to witness the launch of biologic agents that target the disease pathway specifically, including IL-17/IL-17R receptor inhibitors. Drugs such as brodalumab, guselkumab, and tildrakizumab are undergoing Phase III clinical trials.
According to the report, factors such as the dominance of market by biologics will drive this market's growth prospects for the near future. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals. These drugs will continue to outperform other pharmaceuticals in terms of product sales as there is an increasing need for innovative products as effective treatment options for a range of indications.
Further, the report states that one challenge impeding this market's growth is the physician's reluctance to prescribe biosimilars.
Johnson & Johnson
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Psoriasis: Condition overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by type of molecule
PART 09: Market segmentation by mechanism of action
PART 10: Market segmentation by severity of disease